Literature DB >> 26614432

Epithelial-mesenchymal transition plays a critical role in drug resistance of hepatocellular carcinoma cells to oxaliplatin.

Jun Li Ma1, Shan Zeng1, Yan Zhang1, Gan Lu Deng1, Hong Shen2.   

Abstract

Drug resistance is one characteristic of hepatocellular carcinoma (HCC) and can affect the prognosis of patients directly. To explore drug resistance well, we established an oxaliplatin (OXA)-resistant cell line Bel-7402/OXA by exposure to gradually increased concentration of OXA. Some biological characters, such as proliferation, migration, and invasion, were studied. Drug sensitivity and the mechanisms of drug resistance were also investigated. We found that the resistant index of Bel-7402/OXA was 8.3. In comparison with Bel-7402, the percentages of cells in S and G2/M phase were increased. The nature apoptosis rate and drug-after apoptosis rate were all decreased in Bel-7402/OXA, as compared to Bel-7402. Bel-7402/OXA acquired increased migration and invasion ability with epithelial-mesenchymal transition (EMT) phenotype. Knockdown of EMT transcription factor Snail could reverse EMT and sensitized Bel-7402/OXA cells to OXA. EMT was one mechanism of drug resistance and may be a novel target of treatment for drug resistance.

Entities:  

Keywords:  Drug resistance; Epithelial–mesenchymal transition; Hepatocellular carcinoma; Oxaliplatin

Mesh:

Substances:

Year:  2015        PMID: 26614432     DOI: 10.1007/s13277-015-4458-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  17 in total

1.  Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines.

Authors:  Anthony D Yang; Fan Fan; E Ramsay Camp; George van Buren; Wenbiao Liu; Ray Somcio; Michael J Gray; Haiyun Cheng; Paulo M Hoff; Lee M Ellis
Journal:  Clin Cancer Res       Date:  2006-07-15       Impact factor: 12.531

Review 2.  Oxaliplatin-based chemotherapy: a new option in advanced hepatocellular carcinoma. a systematic review and pooled analysis.

Authors:  F Petrelli; A Coinu; K Borgonovo; M Cabiddu; M Ghilardi; V Lonati; S Barni
Journal:  Clin Oncol (R Coll Radiol)       Date:  2014-05-21       Impact factor: 4.126

3.  Role of gap junction intercellular communication in testicular leydig cell apoptosis induced by oxaliplatin via the mitochondrial pathway.

Authors:  Xuhui Tong; Xi Han; Binbin Yu; Meiling Yu; Guojun Jiang; Jie Ji; Shuying Dong
Journal:  Oncol Rep       Date:  2014-10-29       Impact factor: 3.906

4.  FOLFOX-4 vs. doxorubicin for hepatocellular carcinoma: could a negative result be accepted as positive?

Authors:  Alexandre Liccioni; Maria Reig; Jordi Bruix
Journal:  J Hepatol       Date:  2014-03-27       Impact factor: 25.083

Review 5.  Epithelial-mesenchymal transition and drug resistance: role, molecular mechanisms, and therapeutic strategies.

Authors:  Hua Sui; Lei Zhu; Wanli Deng; Qi Li
Journal:  Oncol Res Treat       Date:  2014-09-16       Impact factor: 2.825

6.  Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.

Authors:  Thiruvengadam Arumugam; Vijaya Ramachandran; Keith F Fournier; Huamin Wang; Lauren Marquis; James L Abbruzzese; Gary E Gallick; Craig D Logsdon; David J McConkey; Woonyoung Choi
Journal:  Cancer Res       Date:  2009-07-07       Impact factor: 12.701

7.  Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study.

Authors:  Shukui Qin; Ying Cheng; Jun Liang; Lin Shen; Yuxian Bai; Jianfeng Li; Jia Fan; Lijian Liang; Yaqi Zhang; Gang Wu; Kun-Ming Rau; Tsai-Shen Yang; Zhixiang Jian; Houjie Liang; Yan Sun
Journal:  Oncologist       Date:  2014-09-15

8.  Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines.

Authors:  Kazuya Uchibori; Atsushi Kasamatsu; Masahiko Sunaga; Satoshi Yokota; Tomoya Sakurada; Eriko Kobayashi; Masaharu Yoshikawa; Katsuhiro Uzawa; Shiro Ueda; Hideki Tanzawa; Nobunori Sato
Journal:  Int J Oncol       Date:  2011-12-15       Impact factor: 5.650

9.  Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters.

Authors:  M Saxena; M A Stephens; H Pathak; A Rangarajan
Journal:  Cell Death Dis       Date:  2011-07-07       Impact factor: 8.469

10.  Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells.

Authors:  Paulina Grygielewicz; Barbara Dymek; Anna Bujak; Pawel Gunerka; Aleksandra Stanczak; Monika Lamparska-Przybysz; Maciej Wieczorek; Karolina Dzwonek; Daria Zdzalik
Journal:  Gastric Cancer       Date:  2014-11-19       Impact factor: 7.370

View more
  15 in total

Review 1.  Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?

Authors:  Jente van Staalduinen; David Baker; Peter Ten Dijke; Hans van Dam
Journal:  Oncogene       Date:  2018-07-12       Impact factor: 9.867

2.  Oxymatrine reverses 5-fluorouracil resistance by inhibition of colon cancer cell epithelial-mesenchymal transition and NF-κB signaling in vitro.

Authors:  Li Liang; Jun Wu; Jie Luo; Li Wang; Zu Xuan Chen; Cheng Long Han; Ting Qing Gan; Jie An Huang; Zheng Wen Cai
Journal:  Oncol Lett       Date:  2019-11-13       Impact factor: 2.967

3.  Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin.

Authors:  Yong Hu; Jialan Zang; Xiaobing Qin; Dali Yan; Haixia Cao; Leilei Zhou; Jie Ni; Shaorong Yu; Jianzhong Wu; Ji-Feng Feng
Journal:  Onco Targets Ther       Date:  2017-04-28       Impact factor: 4.147

4.  The anti-tumor activities of Neferine on cell invasion and oxaliplatin sensitivity regulated by EMT via Snail signaling in hepatocellular carcinoma.

Authors:  Ganlu Deng; Shan Zeng; Junli Ma; Yan Zhang; Yanling Qu; Ying Han; Ling Yin; Changjing Cai; Cao Guo; Hong Shen
Journal:  Sci Rep       Date:  2017-01-30       Impact factor: 4.379

5.  Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.

Authors:  Jiejie Dong; Bo Zhai; Weihua Sun; Fengli Hu; Hao Cheng; Jun Xu
Journal:  PLoS One       Date:  2017-09-21       Impact factor: 3.240

6.  Eyes absent homologue 2 predicts a favorable prognosis in colorectal cancer.

Authors:  Jie Zheng; Fuao Cao; Xiaopei Huang; Kuvaneshan Ramen; Xiaowen Xu; Yan Zhu; Wenjun Chang; Yunfeng Shan; Aizhen Guo
Journal:  Onco Targets Ther       Date:  2018-08-08       Impact factor: 4.147

7.  Novel compound cedrelone inhibits hepatocellular carcinoma progression via PBLD and Ras/Rap1.

Authors:  Jiansong Wu; Qiang Niu; Jie Yuan; Xiaodan Xu; Liuxia Cao
Journal:  Exp Ther Med       Date:  2019-10-07       Impact factor: 2.447

8.  Dihydroartemisinin inhibits EMT induced by platinum-based drugs via Akt-Snail pathway.

Authors:  Yuan Qin; Guang Yang; Meng Li; Hui-Juan Liu; Wei-Long Zhong; Xue-Qin Yan; Kai-Liang Qiao; Jia-Huan Yang; Deng-Hui Zhai; Wei Yang; Shuang Chen; Hong-Gang Zhou; Tao Sun; Cheng Yang
Journal:  Oncotarget       Date:  2017-10-10

9.  ZEB1 Promotes Oxaliplatin Resistance through the Induction of Epithelial - Mesenchymal Transition in Colon Cancer Cells.

Authors:  Cao Guo; Junli Ma; Ganlu Deng; Yanlin Qu; Ling Yin; Yiyi Li; Ying Han; Changjing Cai; Hong Shen; Shan Zeng
Journal:  J Cancer       Date:  2017-09-30       Impact factor: 4.207

10.  Treatment with a new benzimidazole derivative bearing a pyrrolidine side chain overcomes sorafenib resistance in hepatocellular carcinoma.

Authors:  Fat-Moon Suk; Chao-Lien Liu; Ming-Hua Hsu; Yu-Ting Chuang; Jack P Wang; Yi-Jen Liao
Journal:  Sci Rep       Date:  2019-11-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.